These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 31428295)

  • 1. Correlate the
    Lyu H; Li M; Jiang Z; Liu Z; Wang X
    Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
    Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtyping of head and neck squamous cell cancers based on immune signatures.
    Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
    Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
    Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting therapeutic responses in head and neck squamous cell carcinoma from
    Wei M; Zhi J; Li L; Wang W
    Transl Cancer Res; 2023 Dec; 12(12):3604-3617. PubMed ID: 38197078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    Transl Oncol; 2018 Oct; 11(5):1171-1187. PubMed ID: 30059832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients.
    Sacconi A; Muti P; Pulito C; Urbani G; Allegretti M; Pellini R; Mehterov N; Ben-David U; Strano S; Bossi P; Blandino G
    Mol Cancer; 2023 Nov; 22(1):192. PubMed ID: 38031025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.
    Wichmann G; Rosolowski M; Krohn K; Kreuz M; Boehm A; Reiche A; Scharrer U; Halama D; Bertolini J; Bauer U; Holzinger D; Pawlita M; Hess J; Engel C; Hasenclever D; Scholz M; Ahnert P; Kirsten H; Hemprich A; Wittekind C; Herbarth O; Horn F; Dietz A; Loeffler M;
    Int J Cancer; 2015 Dec; 137(12):2846-57. PubMed ID: 26095926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
    Zhou G; Liu Z; Myers JN
    J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
    Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
    Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
    Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
    JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations.
    Tuna M; Amos CI; Mills GB
    Neoplasia; 2019 Feb; 21(2):197-205. PubMed ID: 30616092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.
    Lindenbergh-van der Plas M; Brakenhoff RH; Kuik DJ; Buijze M; Bloemena E; Snijders PJ; Leemans CR; Braakhuis BJ
    Clin Cancer Res; 2011 Jun; 17(11):3733-41. PubMed ID: 21467160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.